VVOS Quote, Financials, Valuation and Earnings

Atossa Therapeutics, Inc. has a net margin of -79.61% compared to Vivos Therapeutics, Inc.'s net margin of --. Vivos Therapeutics, Inc.'s return on equity of -315.1% beat Atossa Therapeutics, Inc.'s return on equity of -47.46%.

Vivos Therapeutics, Inc. has a consensus price target of $5.50, signalling upside risk potential of 155.81%. On the other hand Atossa Therapeutics, Inc. has an analysts' consensus of $5.69 which suggests that it could grow by 648.85%. Given that Atossa Therapeutics, Inc. has higher upside potential than Vivos Therapeutics, Inc., analysts believe Atossa Therapeutics, Inc. is more attractive than Vivos Therapeutics, Inc..

Vivos Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Atossa Therapeutics, Inc. has a beta of 0.950, suggesting its less volatile than the S&P 500 by 4.956%.

Vivos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Atossa Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vivos Therapeutics, Inc. pays -- of its earnings as a dividend. Atossa Therapeutics, Inc. pays out -- of its earnings as a dividend.

Vivos Therapeutics, Inc. quarterly revenues are $6.8M, which are larger than Atossa Therapeutics, Inc. quarterly revenues of --. Vivos Therapeutics, Inc.'s net income of -$5.4M is higher than Atossa Therapeutics, Inc.'s net income of -$8.7M. Notably, Vivos Therapeutics, Inc.'s price-to-earnings ratio is -- while Atossa Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vivos Therapeutics, Inc. is 1.07x versus -- for Atossa Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Celldex Therapeutics, Inc. has a net margin of -79.61% compared to Vivos Therapeutics, Inc.'s net margin of -7753.43%. Vivos Therapeutics, Inc.'s return on equity of -315.1% beat Celldex Therapeutics, Inc.'s return on equity of -32.17%.

Vivos Therapeutics, Inc. has a consensus price target of $5.50, signalling upside risk potential of 155.81%. On the other hand Celldex Therapeutics, Inc. has an analysts' consensus of $53.14 which suggests that it could grow by 79.54%. Given that Vivos Therapeutics, Inc. has higher upside potential than Celldex Therapeutics, Inc., analysts believe Vivos Therapeutics, Inc. is more attractive than Celldex Therapeutics, Inc..

Vivos Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Celldex Therapeutics, Inc. has a beta of 1.133, suggesting its more volatile than the S&P 500 by 13.281%.

Vivos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celldex Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vivos Therapeutics, Inc. pays -- of its earnings as a dividend. Celldex Therapeutics, Inc. pays out -- of its earnings as a dividend.

Vivos Therapeutics, Inc. quarterly revenues are $6.8M, which are larger than Celldex Therapeutics, Inc. quarterly revenues of --. Vivos Therapeutics, Inc.'s net income of -$5.4M is higher than Celldex Therapeutics, Inc.'s net income of -$67M. Notably, Vivos Therapeutics, Inc.'s price-to-earnings ratio is -- while Celldex Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vivos Therapeutics, Inc. is 1.07x versus 755.79x for Celldex Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Kiora Pharmaceuticals, Inc. has a net margin of -79.61% compared to Vivos Therapeutics, Inc.'s net margin of 84.08%. Vivos Therapeutics, Inc.'s return on equity of -315.1% beat Kiora Pharmaceuticals, Inc.'s return on equity of -34.44%.

Vivos Therapeutics, Inc. has a consensus price target of $5.50, signalling upside risk potential of 155.81%. On the other hand Kiora Pharmaceuticals, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 411.63%. Given that Kiora Pharmaceuticals, Inc. has higher upside potential than Vivos Therapeutics, Inc., analysts believe Kiora Pharmaceuticals, Inc. is more attractive than Vivos Therapeutics, Inc..

Vivos Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Kiora Pharmaceuticals, Inc. has a beta of -0.753, suggesting its less volatile than the S&P 500 by 175.254%.

Vivos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kiora Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vivos Therapeutics, Inc. pays -- of its earnings as a dividend. Kiora Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Vivos Therapeutics, Inc. quarterly revenues are $6.8M, which are larger than Kiora Pharmaceuticals, Inc. quarterly revenues of --. Vivos Therapeutics, Inc.'s net income of -$5.4M is lower than Kiora Pharmaceuticals, Inc.'s net income of $26.8K. Notably, Vivos Therapeutics, Inc.'s price-to-earnings ratio is -- while Kiora Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vivos Therapeutics, Inc. is 1.07x versus -- for Kiora Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intellia Therapeutics, Inc. has a net margin of -79.61% compared to Vivos Therapeutics, Inc.'s net margin of -735.19%. Vivos Therapeutics, Inc.'s return on equity of -315.1% beat Intellia Therapeutics, Inc.'s return on equity of -54.66%.

Vivos Therapeutics, Inc. has a consensus price target of $5.50, signalling upside risk potential of 155.81%. On the other hand Intellia Therapeutics, Inc. has an analysts' consensus of $24.85 which suggests that it could grow by 130.31%. Given that Vivos Therapeutics, Inc. has higher upside potential than Intellia Therapeutics, Inc., analysts believe Vivos Therapeutics, Inc. is more attractive than Intellia Therapeutics, Inc..

Vivos Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intellia Therapeutics, Inc. has a beta of 2.133, suggesting its more volatile than the S&P 500 by 113.344%.

Vivos Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vivos Therapeutics, Inc. pays -- of its earnings as a dividend. Intellia Therapeutics, Inc. pays out -- of its earnings as a dividend.

Vivos Therapeutics, Inc. quarterly revenues are $6.8M, which are smaller than Intellia Therapeutics, Inc. quarterly revenues of $13.8M. Vivos Therapeutics, Inc.'s net income of -$5.4M is higher than Intellia Therapeutics, Inc.'s net income of -$101.3M. Notably, Vivos Therapeutics, Inc.'s price-to-earnings ratio is -- while Intellia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vivos Therapeutics, Inc. is 1.07x versus 17.75x for Intellia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.